TP53 and cancer: This expanding body of Saudi research spans classical markers such as TP53, BRCA1/2, and PIK3CA, alongside emerging targets related to cuproptosis, inflammation, and multidrug resistance, collectively underscoring the growing integration of biomarker discovery into the national cancer drug development pipeline [9, 87].